Welcome to the Center for Infection and Immunity of Lille
Follow us on
The Center for Infection & Immunity of Lille (CIIL) develops research projects on the molecular and cellular mechanisms of infectious and chronic inflammatory diseases with the aim to apply this knowledge to the development of improved diagnostics, vaccines and therapeutics. To achieve these goals, our Center gathers complementary expertise, covering a wide range of disciplines from epidemiology, molecular and cellular virology, bacteriology and parasitology, to the immunological basis of infectious and non-infectious diseases and translation into clinical applications. The CIIL studies bacterial, viral and parasitic diseases and the immune reaction against these infections as well as related immune dysfunctions of non-infectious diseases such as allergic asthma and chronic obstructive pulmonary disease (COPD). We also work on opportunistic infections in the context of cystic fibrosis which is the most frequent human genetic disease. The major infectious diseases that we investigate are tuberculosis, pneumococcal pneumonia, whooping cough, plague, hepatitis C and E, influenza, Middle East respiratory syndrome (MERS), malaria, schistosomiasis, toxoplasmosis, cryptosporidiosis and blastocystosis.
Jean DUBUISSON, Director
ITMO I3M annual conference on February 4th, at the Pasteur Institute of Lille.
HERE for more details.
Le métabolisme du tryptophane, un acide aminé essentiel, connait un regain d'intérêt ces dernières années ...
De plus en plus d'études s’intéressent à ses produits de dégradations qui sont impliqués dans la régulation de mécanismes neurologiques, physiologiques, toxicologiques ou immunologiques. Pour cette raison nous avons souhaité organiser une rencontre scientifique centrée sur cette thématique mais rassemblant des chercheurs impliqués dans différents domaines de recherche.
Plus de détail ICI
WHO’s first global review of antibacterial products in preclinical development These products target WHO priority pathogens, Mycobacterium tuberculosis and Clostridium difficile ...
Further detail: HERE
From another perspective
More than 60 diseases can be transmitted to humans by rats. Among them, Plague, believed to be a disease of the past, has never been eradicated ...
In 2017 in Madagascar, there was one of the largest plague epidemics of the last 25 years. Plague, cause by the bacterium Yersinia pestis, is a flea-borne zoonosis. Antibiotic-resistant Y. pestis starts to appear leading the World Health Organization to raise the alarm Bell. The research units of the Institutes Pasteur of Lille and Paris are investigating the disease to better understand it and find new cures.
Attractive packages to internationally-renowned researchers wishing to join the CIIL or lead a network project involving a team of the CIIL! Contact us rapidly to prepare your application at: firstname.lastname@example.org
Join us in Lille!
FAIR project: investigating treatments for antibiotic-resistant pneumonia
An international consortium of interdisciplinary specialists is set to a launch a new European Union (EU) wide research project that will focus on improving the treatment of antibiotic-resistant pneumonia.
Pneumonia is a type of respiratory tract infection that causes the tiny air sacs in the lungs (called alveoli) to become inflamed and fill with fluid, making it difficult to breathe. Despite often being preventable, pneumonia is the third leading cause of death worldwide and it especially affects children and the elderly.
The new research initiative, called FAIR , gathers experts from several of Europe’s leading medical and scientific institutions, including the ERS. It will receive a total of €10 million in funding from EU Horizon 2020 grants over five years, beginning in January 2020 until December 2024.
Further information: HERE
Ruben Hartkoorn has successfully obtained an ERC consolidator grant (2 million euros over 5 years) for his research program ...
ANTIBIOCLICKS that will develop new ways of vectorising antibiotics to fight antimicrobial drug resistance! Antibiotic resistance is one of the most serious threats to global health today, and it risks bringing us back to the time when common treatments for conditions like pneumonia and tuberculosis were lacking. A major obstacle in combatting bacteria is their impermeable cell wall and cell membrane. The ANTIBIOCLICKS program will exploit a newly discovered natural chemical reaction that will allow for bioinspired modification of antibiotics so that bacteria actively take them up. This type of “Trojan Horse” strategy offers a new therapeutic perspective. The five-year project will begin in May 2020. Ruben Hartkoorn, is an Inserm researcher that heads the Chemical Biology of Antibiotics team within the Lille Center for Infection and Immunity of Lille (University of Lille / CNRS / Inserm / Institut Pasteur de Lille / CHU Lille).
Post-doctoral position in immunotherapy of bacterial infections at the Institut Pasteur de Lille
For more details: HERE
Post-doctoral position in cell biology of bacterial infections at the Institut Pasteur de Lille
For more details: HERE
European Respiratory Journal. 2020
PLoS Pathog. 2019
Chemical Reviews. 2019
PLoS Biol. 2019
ACS Nano. 2019
The CRB-EPLS (Centre de Recherche Biomédicale - Espoir Pour La Santé) is a Senegalese non-profit clinical research structure created in 1995 in Saint- Louis in Northern Senegal. This sub-saharian institution is attached to the CIIL as a clinical research field facility and is associated with the Institute Pasteur in Lille as part of the International Network of Pasteur Institutes. The activities of the CRB-EPLS are carried out by more than 40 employees on nearly 2000 m2 of premises. The Center has accessed to rural as well as urban areas in the Senegal River Basin and works in close collaboration with local health authorities. It focuses its investigations on major infectious diseases such as schistosomiasis, malaria or tuberculosis and the associated immune responses. The CRB-EPLS also carries out research on undernutrition among children and non-communicable chronic diseases such as hypertension, obesity and diabetes. CRB-EPLS is renowned for providing a high quality service for the management of clinical trials from Phase 1 to Phase 3 on public health issues specific to sub-Saharan countries.
The SF2i will promote two major common research themes focused on infection and inflammation. This will include translational developments of innovative experimental models and technologies. Focusing on infection and inflammation is also mean to increase further the visibility for the institutions and the patients. Specific efforts will be made to understand and characterize co-morbidities associated with infections and inflammation, susceptibility to infection in patients, especially patients with immune-mediated inflammatory diseases, and the role of infections in further development and in the progression of chronic inflammation and fibrosis.
The SF2i’s project is fully in line with national and local health and research strategies. As a continuation of the SF3i (2015-2019), the SF2i will help to “structure local research around academic research clusters of excellence”. The CIIL and INFINITE research centers have already structured their own research activities for 2020-2024 through the renewal and optimization of existing core structures. It is expected that further structuring will increase the research centers’ impact on regional, national and European funding agencies and will position infectious and inflammatory diseases as a unique scientific center of excellence in Lille, as is currently the case for neuroscience and cancer.
The SF2i will thus federate and develop multidisciplinary, integrated research on pathogenic microorganisms and inflammatory diseases that affect humans within the "One Health" framework adopted by the WHO.
Accordingly, the SF2i will have to strengthen the above-mentioned themes by initiating and developing educational programs, training, and dissemination activities in the field of infection and inflammation.
Director: Benoit Foligné
Deputy director: Jean-Claude Sirard